Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Mo Qatanani Sells 68,510 Shares

Scholar Rock Holding Co. (NASDAQ:SRRK) insider Mo Qatanani sold 68,510 shares of the firm’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the completion of the transaction, the insider now directly owns 111,084 shares in the company, valued at approximately $4,154,541.60. This represents a 38.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Scholar Rock Trading Down 3.7 %

Shares of Scholar Rock stock opened at $37.70 on Friday. The firm has a market capitalization of $3.53 billion, a PE ratio of -16.04 and a beta of 0.50. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm’s 50 day moving average is $41.81 and its 200 day moving average is $28.51. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98.

Institutional Investors Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP grew its holdings in shares of Scholar Rock by 16.2% during the 3rd quarter. Wellington Management Group LLP now owns 199,777 shares of the company’s stock valued at $1,600,000 after purchasing an additional 27,801 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Scholar Rock by 9.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock worth $4,027,000 after buying an additional 42,139 shares during the period. Barclays PLC boosted its position in Scholar Rock by 103.4% during the 3rd quarter. Barclays PLC now owns 165,449 shares of the company’s stock worth $1,324,000 after buying an additional 84,118 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Scholar Rock by 7.1% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company’s stock worth $759,000 after buying an additional 6,269 shares during the period. Finally, Geode Capital Management LLC boosted its position in Scholar Rock by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,543,025 shares of the company’s stock worth $12,361,000 after buying an additional 120,489 shares during the period. 91.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. Truist Financial raised their target price on shares of Scholar Rock from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. Wedbush reissued an “outperform” rating and issued a $47.00 target price on shares of Scholar Rock in a report on Wednesday, January 29th. Finally, HC Wainwright raised their target price on shares of Scholar Rock from $40.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $40.43.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.